Biological Products, (No Diagnostic Substances) · CIK 1711279
Krystal Biotech develops and commercializes gene therapies for rare diseases like DEB, cystic fibrosis, and alpha-1 antitrypsin deficiency
Comparable business profile · signals at a glance
Coverage (30d): 1 reputable article · skews ▲ positive.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
In the 90 days to Mar 4, 2026: 5 sold $63.1M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 8,798 | $264.85 | $2.3M |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 6,000 | $265.16 | $1.6M |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 4,852 | $264.64 | $1.3M |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 3,667 | $260.37 | $955K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 3,128 | $260.49 | $815K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 2,962 | $261.41 | $774K |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 2,931 | $261.41 | $766K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 2,439 | $265.59 | $648K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 2,380 | $262.44 | $625K |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 2,248 | $263.58 | $593K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 2,043 | $263.70 | $539K |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 1,938 | $262.35 | $508K |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 1,700 | $266.42 | $453K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 1,377 | $259.87 | $358K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 920 | $266.56 | $245K |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 668 | $259.61 | $173K |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 589 | $258.54 | $152K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 483 | $257.31 | $124K |
| Mar 4, 2026 | Krishnan Krish SPresident and CEO | Sell | 470 | $258.38 | $121K |
| Mar 4, 2026 | Krishnan SumaPresident, R&D | Sell | 407 | $257.32 | $105K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.